Hackensack Meridian Health

57 total trials 48 currently recruiting 6 completed

Trial Pipeline

RECRUITING Phase 1

Ceftriaxone for Post-Treatment Lyme Disease

NCT06785402

RECRUITING Phase 2

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

NCT07214688

RECRUITING

Predictive Value of Lung Ultrasound for Respiratory Decompensation in Late Preterm Neonates

NCT07216053

RECRUITING NA

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

NCT07011342

RECRUITING NA

OBWELL: Innovative Psychotherapeutic Intervention to Treat Postpartum Depression

NCT06991166

RECRUITING NA

Transitions of Care Clinic (TOCC)

NCT06937827

RECRUITING Phase 2

Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy

NCT06798558

RECRUITING NA

Leveraging the Emergency Department (LEAD) Study

NCT06605534

RECRUITING

CanScan; Community-based Registry to Assess, Address and advaNce SCreening for cANcer Prevention and Management

NCT06804395

RECRUITING NA

Endometrial Cell Collection With the PadKit

NCT06464107

RECRUITING Phase 2

Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma

NCT05726383

RECRUITING NA

Support for Cancer Patients Awaiting News

NCT06199570

RECRUITING Phase 4

Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients

NCT05776953

RECRUITING Phase 2

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229

RECRUITING Early Phase 1

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

NCT05657990

RECRUITING NA

Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)

NCT05651945

RECRUITING Phase 1

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

NCT05199311

RECRUITING

ETMR One: An International Registry and Research Platform for Children With Embryonal Tumor With Multilayer Rosettes

NCT04794686

RECRUITING Phase 2

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft

NCT04263025

RECRUITING Phase 1

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

NCT03909412

RECRUITING Phase 1

Post-operative Urinary Retention (POUR) Following Thoracic Surgery

NCT03609580

ACTIVE NOT RECRUITING Early Phase 1

Respiratory Transition Without Continuous Positive Airway Pressure

NCT07390812

ACTIVE NOT RECRUITING Phase 1

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT02446236

ACTIVE NOT RECRUITING Phase 1

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT01297764

COMPLETED

Central Venous Access Study

NCT03480542

COMPLETED Phase 2

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

NCT01453101

COMPLETED Phase 2

Pediatric Head Lice Study Product Comparison

NCT02213055

COMPLETED Phase 1

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823

COMPLETED

Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations

NCT00456209

COMPLETED Phase 2

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

NCT00004906

What the Pipeline for Hackensack Meridian Health Shows

According to the ClinicalTrials.gov registry, Hackensack Meridian Health is linked to 57 US clinical trials across every stage of research activity. Of those, 48 studies are currently recruiting — about 84% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Hackensack Meridian Health reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 17 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Hackensack Meridian Health is Multiple Myeloma with 5 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial